New drug in development displays positive result for patients with rare type of cancer
Researchers at the Moffitt Cancer Center (Tampa, FL, USA) have displayed that patients with metastatic midgut neuroendocrine tumors that were treated with a new drug – lutetium-177 (177Lu)-Dotatate – showed markedly improved progression free survival compared with those treated with traditional treatments.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.